drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
An autologous anti-DLL3 chimeric antigen receptor (CAR) T-cell therapy composed of genetically engineered patient T cells expressing a CAR targeting Delta-like ligand 3 (DLL3). Binding of DLL3 triggers T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of DLL3-positive tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting DLL3. CAR engagement of DLL3 on tumor cells activates the T cells, inducing cytokine release, expansion, and perforin/granzyme-mediated cytotoxic killing of DLL3-positive tumor cells.
drug_name
SNC115
nct_id_drug_ref
NCT06384482